Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom—Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.
Concrete barriers preventing dementia trial participation in the UK are identifiable and fixable through better data systems and community engagement.
This report from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme identifies structural barriers impeding dementia clinical trial access in the UK, including data infrastructure gaps, underrepresentation of minority populations, and regulatory complexity. The panel proposes concrete recommendations including NHS data linkage, community-based patient registries, and streamlined consent processes to improve trial enrollment and equity.
What the study was
- Study design
- expert_report
- Category
- neurodegenerative disease / aging
- Maturity
- Exploratory
- Journal
- Alzheimer's and Dementia
Why it surfaced
Report from high-profile UK dementia advisory board (co-authored by John Hardy, tau/APP hypothesis pioneer) identifying actionable barriers to dementia trials. Dementia is among the highest unmet-need conditions in aging populations. Recommendations could accelerate the drug discovery pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.